MapLight Therapeutics (MPLT) Leases (2024 - 2025)

MapLight Therapeutics recorded quarterly Leases of $5.5 million in Q4 2025, down 3.89% quarter-over-quarter from $5.7 million in Q3 2025, and down 13.63% year-over-year from $6.4 million in Q4 2024.

MapLight Therapeutics' Leases history runs 2 years deep, the most recent figure standing at $5.5 million for Q4 2025.

  • In Q4 2025, Leases fell 13.63% year-over-year to $5.5 million; the TTM figure through Dec 2025 stood at $5.5 million (down 13.63% YoY), while the FY2025 annual figure was $5.5 million, down 13.63% from the prior year.
  • Leases came in at $5.5 million for Q4 2025 at MapLight Therapeutics, down from $5.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $6.4 million in Q4 2024 to a low of $5.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Leases (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 83,048.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - 61,822.50
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 285.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 1.69 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 189.30 Mn
10 MapLight Therapeutics 254.43 Mn 254.43 Mn - 5.49 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 5.49 Mn
Sep 30, 2025 5.71 Mn
Dec 31, 2024 6.35 Mn